LOS ANGELES, Oct. 20, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises R1 RCM Inc. (“RCM” or “the Company”) (NASDAQ: RCM) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors.

NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM ). The investigation concerns whether RCM and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Aug 1, 2024 · R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9...

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888 …

On Oct. 16, 2023, financial fraud investigator Jehoshaphat Research published a scathing forensic report accusing R1 RCM of engaging in misrepresentative accounting and calling its stock “practically uninvestible today.”

Aug 2, 2024 · TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R), through their affiliated investment funds, are set to acquire healthcare technology company R1 RCM in an all-cash transaction valued at nearly $8.9bn.

With unparalleled access to data, intelligent technologies, and advanced analytics – all built and backed by deep RCM experts – we help leading providers transform their approach to financial performance and patient care, today and tomorrow.

On July 31, 2024, R1 RCM Inc. (R1) announced that they have entered into a definitive agreement pursuant to which investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice will acquire R1, a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

Aug 1, 2024 · Kirkland & Ellis advised healthcare services provider R1 RCM Inc. (NASDAQ: RCM) on a definitive agreement to be acquired in an all-cash transaction with an enterprise value of $8.9 billion by investment funds affiliated with investment management firm TowerBrook Capital Partners and private investment firm Clayton, Dubilier & Rice (CD&R).

According to R1 RCM 's latest financial reports the company's current revenue (TTM ) is HK$19.18 Billion. In 2023 the company made a revenue of HK$17.60 Billion an increase over the revenue in the year 2022 that were of HK$14.10 Billion.